Phase 2 N=25 NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=118 Prostaglandin Inhibition for Emphysema
Emphysema
Primary: Will Ibuprofen, 600 mg Three Times Daily, Decrease PGE Concentration in the Alveolar Portion of BAL Fluid in Subjects With Emphysema in Comparison to Placebo? — 0.003…
Phase 4 N=49 Effects of Linagliptin on Endothelial Function
Type 2 Diabetes · Coronary Artery Disease
Primary: Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks — 0.4; -0.5 percentage of change in diameter (%)
Phase 3 N=2,761 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
Anemia
Primary: Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 — 1.75; 0.40 g/dL — p=<0.001
Phase 4 N=47 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure
Prehypertension · Gout · Pulse Wave Velocity
Primary: Changes in 24 Hour Blood Pressure
Phase 2 N=25 Rituximab in Pretreated Elderly or Unfit B-CLL Patients
B-Cell Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 7 Participants
Phase 1 N=26 Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
HIV
Primary: Number of Grade 2 or Higher Related Adverse Events — 11 Events
Phase 2 N=43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Adult B Acute Lymphoblastic Leukemia · Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Adult Solid Neoplasm
Primary: Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride — 300 mg
Phase 3 N=244 Assessment of Mechanisms of Improved Wound Healing
Burns
Primary: Decrease Hypermetabolism as Measured by Stable Isotope Infusion Study
Phase 2 N=20 Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
X-Linked Hypophosphatemia
Primary: Number of Participants With Adverse Events (AEs), Treatment Emergent AEs (TEAEs), Serious AEs (SAEs), and AEs Leading to Discontinuation or Death — 20; 20; 12; 9…
N/A N=17 Effects of Diet on Brain Processing
HIV · Neurocognitive Impairment
Primary: Neurocognition: Mean Score of Hopkins Verbal Learning Test (Total) at Baseline — 29.4; 31.1 score on a scale
Phase 2 N=24 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Metastatic Ureter Carcinoma · Metastatic Urethral Carcinoma · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Observed Overall Response Rate — 50 percentage of participants
N/A N=4,350 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)
Diagnostic Errors
Primary: Number of Adolescents Diagnosed With Depression Seen in Well Child Visits — 233; 443 Participants — p=<0.0001
N/A N=216 Improving Communication During a Pandemic Flu Outbreak
Healthy
Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05
Phase 3 N=239 Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Evaluation of the Long-term Safety and Tolerability of Oral Istradefylline (20mg or 40mg/Day [mg/d]) — 141; 98 Participants